Loading... Please wait...

02/2013 Librede Recieves Phase II SBIR Funding From the NIH

Posted

Librede has received NIH SBIR Phase II funding to demonstrate the pharmacology of several ion channels in their droplet based artuifical membrane ion channel platform.